

**UCC Library and UCC researchers have made this item openly available. Please [let us know](#) how this has helped you. Thanks!**

<b>Title</b>	Trial of feasibility and acceptability of routine low-dose aspirin versus early screening test indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial
<b>Author(s)</b>	Mone, Fionnuala; Mulcahy, Cecilia; McParland, Peter; Breathnach, Fionnuala M.; Downey, Paul; McCormack, Dorothy; Culliton, Marie; Stanton, Alice; Cody, Fiona; Morrison, John J.; Daly, Sean; Higgins, John R.; Cotter, Amanda; Hunter, Alyson; Tully, Elizabeth C.; Dicker, Patrick; Alfirevic, Zarko; Malone, Fergal D.; McAuliffe, Fionnuala M.
<b>Publication date</b>	2018
<b>Original citation</b>	Mone, F., Mulcahy, C., McParland, P., Breathnach, F., Downey, P., McCormack, D., Culliton, M., Stanton, A., Cody, F., Morrison, J. J., Daly, S., Higgins, J., Cotter, A., Hunter, A., Tully, E. C., Dicker, P., Alfirevic, Z., Malone, F. D. and McAuliffe, F. M. (2018) 'Trial of feasibility and acceptability of routine low-dose aspirin versus Early Screening Test indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial', <i>BMJ Open</i> , 8(7), e022056 (9pp). doi: 10.1136/bmjopen-2018-022056
<b>Type of publication</b>	Article (peer-reviewed)
<b>Link to publisher's version</b>	<a href="https://bmjopen.bmj.com/content/8/7/e022056">https://bmjopen.bmj.com/content/8/7/e022056</a> <a href="http://dx.doi.org/10.1136/bmjopen-2018-022056">http://dx.doi.org/10.1136/bmjopen-2018-022056</a> Access to the full text of the published version may require a subscription.
<b>Rights</b>	© 2018, the Author(s) (or their employer(s)). This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <a href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</a> . <a href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</a>
<b>Item downloaded from</b>	<a href="http://hdl.handle.net/10468/6940">http://hdl.handle.net/10468/6940</a>



Downloaded on 2019-10-18T23:31:10Z



Adverse/Serious Adverse Event	Low dose Aspirin Group 1 N=179	No-aspirin Group 2 N=183	Screen and treat Group 3 N=184
Adverse events			
Vaginal spotting No. (%)	27 (15.1)	18 (9.8)	12 (6.5)
Post-partum haemorrhage No. (%)			
>500mls	25 (13.0)	9 (4.9)	12 (6.5)
>1000mls	7 (3.6%)	1 (0.5)	4 (2.2)
Serious Adverse Events			
NICU admission	9 (5.0)	7 (3.8)	9 (4.9)
Perinatal Death	2 (1.1)	2 (1.1)	2 (1.1)
Maternal admission	18 (10.1)	15 (8.2)	14 (7.6)
Congenital anomaly	3 (1.7)	4 (2.2)	3 (1.6)
Total serious adverse events	32 (17.8)	28 (15.3)	28 (15.2)

Table S3 – Adverse and serious adverse events in all three groups. There may be >1 adverse event or serious adverse event per subject